Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Category: #health  By Dhananjay Punekar  Date: 2018-06-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne muscular dystrophy (DMD), a rare degenerative genetic disease.

Reportedly, DMD causes muscle wasting in patients and can prove to be incurable after the patients attain the age of 30. The symptoms of ailment are observed in children between the age of three to five years with boys being more prone to the disease as compared to girls.

Sarepta Therapeutics had shared the experimental outcomes from three children, who were treated with the gene therapy during a phase 1/2a clinical test. The outcomes derived from the experiments on the first three patients registered in the phase 1/2a trial displayed an improvement in micro-dystrophin, a shorter kind of dystrophin gene. A mutation in this gene is witnessed in the patients affected from DMD, leading to the low production of protein dystrophin and eventually, muscle wasting.

Additionally, the phase 1/2a trials demonstrated that there was a substantial decline in serum creatine kinase enzyme in patients affected due to DMD after they underwent Sarepta’s gene treatment. For the record, creatine is an enzyme linked to muscle damage and is detected at an escalated level in patients suffering from DMD.

Dr. Jerry Mendell, the principal investigator of the phase 1/2a clinical study, has stated that the new gene therapy introduced by Sarepta Therapeutics drastically reduces creatine kinase levels and produces high proportion of protein dystrophin. He further commented that though the outcomes from the trials are preliminary, if they continue to deliver positive results through Sarepta’s gene therapy and are tested in more patients, they will prove to be a breakthrough in DMD treatment.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Novo Nordisk inks pact with Kallyope to tackle obesity & diabetes
Novo Nordisk inks pact with Kallyope to tackle obesity & diabetes
By Dhananjay Punekar

Kallyope Inc., a platform biotech company, and Novo Nordisk A/S, a Denmark based healthcare firm, have declared that they have both signed an option agreement for jointly carrying out research programs to discover new ...